

Marc C Chamberlain

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3167840/publications.pdf>

Version: 2024-02-01

151
papers

12,140
citations

26630

56
h-index

28297

105
g-index

187
all docs

187
docs citations

187
times ranked

11209
citing authors

#	ARTICLE	IF	CITATIONS
1	“You can observe a lot by just watching” (Yogi Berra). <i>Neuro-Oncology</i> , 2022, 24, 125-126.	1.2	0
2	Leptomeningeal metastasis. , 2022, , 133-143.		0
3	A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 1505-1515.	1.2	27
4	PET imaging in patients with brain metastasis—report of the RANO/PET group. <i>Neuro-Oncology</i> , 2019, 21, 585-595.	1.2	139
5	Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1411-1418.	1.2	24
6	Leptomeningeal metastasis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 149, 169-204.	1.8	55
7	Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. <i>Neuro-Oncology</i> , 2018, 20, 13-23.	1.2	74
8	Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. <i>Neuro-Oncology</i> , 2018, 20, 259-267.	1.2	41
9	Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. <i>Neuro-Oncology</i> , 2018, 20, 249-258.	1.2	78
10	Leptomeningeal metastases: a RANO proposal for response criteria. <i>Neuro-Oncology</i> , 2017, 19, now183.	1.2	157
11	Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial. <i>Journal of Neuro-Oncology</i> , 2017, 131, 507-516.	2.9	4
12	Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 and Leukemia, 2017, 17, 225-230.	0.4	17
13	Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. <i>Journal of Neuro-Oncology</i> , 2017, 133, 561-569.	2.9	43
14	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. <i>Neuro-Oncology</i> , 2017, 19, 625-635.	1.2	137
15	Systemic therapy of brain metastases: non—small cell lung cancer, breast cancer, and melanoma. <i>Neuro-Oncology</i> , 2017, 19, i1-i24.	1.2	171
16	Neoplastic Meningitis Due to Lung, Breast, and Melanoma Metastases. <i>Cancer Control</i> , 2017, 24, 22-32.	1.8	20
17	Cerebrospinal Fluid Dissemination and Neoplastic Meningitis in Primary Brain Tumors. <i>Cancer Control</i> , 2017, 24, 1-16.	1.8	40
18	Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. <i>Neuro-Oncology</i> , 2017, 19, 12-21.	1.2	94

#	ARTICLE	IF	CITATIONS
19	Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. <i>Cancer</i> , 2016, 122, 582-587.	4.1	33
20	Recurrent ganglioglioma in adults treated with BRAF inhibitors. <i>CNS Oncology</i> , 2016, 5, 27-29.	3.0	17
21	A selected review of abstracts from the 20th Annual Meeting of the Society for Neuro-Oncology (SNO). <i>CNS Oncology</i> , 2016, 5, 115-119.	3.0	0
22	Neuro-oncology: a selected review of ASCO 2016 abstracts. <i>CNS Oncology</i> , 2016, 5, 193-198.	3.0	0
23	Chemotherapy-Related Neurotoxicity. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 81.	4.2	77
24	Neuro-oncology overview. , 2016, , 557-558.		0
25	Anaplastic astrocytoma. <i>CNS Oncology</i> , 2016, 5, 145-157.	3.0	51
26	Current Management of Adult Diffuse Infiltrative Low Grade Gliomas. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 15.	4.2	23
27	High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma. <i>Journal of Neuro-Oncology</i> , 2016, 126, 545-550.	2.9	22
28	Flow-Related Aneurysm within Glioblastoma: A Case Report and Review of Literature. <i>World Neurosurgery</i> , 2016, 89, 729.e1-729.e6.	1.3	11
29	Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1268-1278.	1.1	58
30	Central Nervous System Cancers, Version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1191-1202.	4.9	89
31	Bevacizumab and other novel therapies for recurrent oligodendroglial tumors. <i>CNS Oncology</i> , 2015, 4, 333-339.	3.0	4
32	Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients. <i>CNS Oncology</i> , 2015, 4, 381-386.	3.0	18
33	Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases. <i>Case Reports in Oncology</i> , 2015, 8, 72-77.	0.7	10
34	Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study. <i>Journal of Neuro-Oncology</i> , 2015, 122, 329-338.	2.9	18
35	The future of high-grade glioma: Where we are and where are we going. , 2015, 6, 9.		29
36	Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors. <i>Journal of Neuro-Oncology</i> , 2015, 125, 249-251.	2.9	37

#	ARTICLE	IF	CITATIONS
37	Complications related to the use of an intraventricular access device for the treatment of leptomeningeal metastases from solid tumor: a single centre experience in 112 patients. <i>Journal of Neuro-Oncology</i> , 2015, 124, 317-323.	2.9	31
38	O6-methylguanine-DNA methyltransferase activity is associated with response to alkylating agent therapy and with MGMT promoter methylation in glioblastoma and anaplastic glioma. <i>BBA Clinical</i> , 2015, 3, 1-10.	4.1	16
39	Glioblastoma in the Elderly. <i>Cancer Treatment and Research</i> , 2015, 163, 159-170.	0.5	2
40	Is the volume of low-grade glioma measurable and is it clinically relevant?. <i>Neuro-Oncology</i> , 2014, 16, 1027-1028.	1.2	4
41	Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. <i>Neuro-Oncology</i> , 2014, 16, 829-840.	1.2	198
42	Is there a role for vaccine-based therapy in recurrent glioblastoma?. <i>Neuro-Oncology</i> , 2014, 16, 757-757.	1.2	3
43	Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series. <i>Journal of Neuro-Oncology</i> , 2014, 118, 155-162.	2.9	34
44	CSF CA 15-3 in breast cancer-related leptomeningeal metastases. <i>Journal of Neuro-Oncology</i> , 2014, 117, 117-124.	2.9	17
45	Lumbar spine neuroarthropathy (Charcot joint) caused by a myxopapillary ependymoma. <i>Journal of Neuro-Oncology</i> , 2014, 117, 375-376.	2.9	1
46	Does early identification of low-grade glioma growth impact outcome?. <i>Neuro-Oncology</i> , 2014, 16, 1296-1296.	1.2	0
47	Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. <i>Neuro-Oncology</i> , 2014, 16, 1541-1546.	1.2	12
48	A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC). <i>Journal of Neuro-Oncology</i> , 2014, 118, 335-343.	2.9	46
49	Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. <i>Neuro-Oncology</i> , 2014, 16, 1176-1185.	1.2	141
50	Central Nervous System Involvement in Cutaneous T-Cell Lymphoma: 2 Illustrative Cases and a Review of Current Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e25-e30.	0.4	6
51	Central Nervous System Cancers, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1517-1523.	4.9	69
52	Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. <i>Journal of Neuro-Oncology</i> , 2013, 114, 237-240.	2.9	124
53	Treatment of primary CNS lymphoma (PCNSL) following successful treatment of systemic non-Hodgkin's lymphoma (NHL): a case series. <i>Journal of Neuro-Oncology</i> , 2013, 113, 27-32.	2.9	5
54	Comprehensive neuraxis imaging in leptomeningeal metastasis: a retrospective case series. <i>CNS Oncology</i> , 2013, 2, 121-128.	3.0	31

#	ARTICLE	IF	CITATIONS
55	Teaching Neuro <i>Images</i> : Sacral spine chloroma. <i>Neurology</i> , 2013, 81, e87.	1.1	8
56	IFN- γ for recurrent surgery- and radiation-refractory high-grade meningioma: a retrospective case series. <i>CNS Oncology</i> , 2013, 2, 227-235.	3.0	30
57	Is there effective systemic therapy for recurrent surgery- and radiation-refractory meningioma?. <i>CNS Oncology</i> , 2013, 2, 1-5.	3.0	11
58	Conference Scene: A selected review of abstracts from the 17th Annual Scientific Meeting of the Society for Neuro-Oncology. <i>CNS Oncology</i> , 2013, 2, 117-120.	3.0	0
59	Salvage intracerebrospinal fluid thiotepa in breast cancer-related leptomeningeal metastases. <i>Anti-Cancer Drugs</i> , 2013, 24, 1093-1097.	1.4	9
60	Are Prognostic Factors for Leptomeningeal Metastases Defined Sufficiently to Permit Tailored Treatment?. <i>Journal of Thoracic Oncology</i> , 2013, 8, e66-e67.	1.1	4
61	Prolonged survival of patients with breast cancer-related leptomeningeal metastases. <i>Anticancer Research</i> , 2013, 33, 2057-63.	1.1	16
62	The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma. <i>Current Opinion in Oncology</i> , 2012, 24, 666-671.	2.4	35
63	Response to Weltman and Fleury Malheiros, re Lassman et al.. <i>Neuro-Oncology</i> , 2012, 14, 677-678.	1.2	0
64	Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 929-936.	2.8	10
65	A novel treatment for glioblastoma: integrin inhibition. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 421-435.	2.8	34
66	Neoplastic Meningitis and Metastatic Epidural Spinal Cord Compression. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 917-931.	2.2	19
67	Carcinomatous meningitis. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 205-209.	0.5	1
68	Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series. <i>Journal of Neuro-Oncology</i> , 2012, 109, 143-148.	2.9	73
69	Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. <i>Journal of Neuro-Oncology</i> , 2012, 107, 315-321.	2.9	81
70	Neuraxis imaging in leptomeningeal metastasis: A retrospective case series.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2046-2046.	1.6	58
71	Medical treatment of recurrent meningiomas. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1425-1432.	2.8	41
72	Radiographic patterns of relapse in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2011, 101, 319-323.	2.9	183

#	ARTICLE	IF	CITATIONS
73	Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2011, 102, 427-432.	2.9	39
74	Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. <i>Journal of Neuro-Oncology</i> , 2011, 104, 765-771.	2.9	66
75	Salvage therapy with single agent bendamustine for recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2011, 105, 523-530.	2.9	25
76	Adult Primary Intradural Spinal Cord Tumors: A Review. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 320-328.	4.2	240
77	Neuro-oncology: a selected review of ASCO 2011 abstracts. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1371-1377.	2.8	1
78	Bevacizumab for the Treatment of Recurrent Glioblastoma. <i>Clinical Medicine Insights: Oncology</i> , 2011, 5, CMO.S7232.	1.3	113
79	Radiation-Induced Myelopathy. <i>Archives of Neurology</i> , 2011, 68, 1608.	4.5	25
80	Lymphomatous meningitis as a presentation of non-Hodgkin lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 419-20.	0.3	2
81	Leptomeningeal metastasis. <i>Current Opinion in Oncology</i> , 2010, 22, 627-635.	2.4	159
82	10 Questions About the Use of Bevacizumab in the Management of Recurrent Malignant Gliomas. <i>Neurologist</i> , 2010, 16, 56-60.	0.7	1
83	Neurotoxicity of Cancer Treatment. <i>Current Oncology Reports</i> , 2010, 12, 60-67.	4.0	27
84	Salvage therapy with single agent bevacizumab for recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2010, 96, 259-269.	2.9	117
85	Intradural intramedullary spinal cord metastasis due to mesothelioma. <i>Journal of Neuro-Oncology</i> , 2010, 97, 133-136.	2.9	24
86	Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. <i>Cancer</i> , 2010, 116, 1947-1952.	4.1	99
87	Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. <i>Cancer</i> , 2010, 116, 3988-3999.	4.1	62
88	Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1168-1174.	1.6	450
89	High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. <i>Neuro-Oncology</i> , 2010, 12, 736-744.	1.2	83
90	Brain metastases: a medical neuro-oncology perspective. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 563-573.	2.8	33

#	ARTICLE	IF	CITATIONS
91	Anticancer therapies and CNS relapse: overcoming bloodâ€‘brain and bloodâ€‘cerebrospinal fluid barrier impermeability. Expert Review of Neurotherapeutics, 2010, 10, 547-561.	2.8	20
92	Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert Review of Neurotherapeutics, 2010, 10, 1537-1544.	2.8	155
93	Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. Journal of Clinical Oncology, 2010, 28, 1963-1972.	1.6	3,222
94	Diagnostic Tools for Neoplastic Meningitis: Detecting Disease, Identifying Patient Risk, and Determining Benefit of Treatment. Seminars in Oncology, 2009, 36, S35-S45.	2.2	189
95	Bevacizumab for recurrent alkylatorâ€‘refractory anaplastic oligodendroglioma. Cancer, 2009, 115, 1734-1743.	4.1	70
96	Neoplastic meningitis. Cancer, 2009, 115, 1941-1946.	4.1	34
97	Temozolomide for recurrent intracranial supratentorial platinumâ€‘refractory ependymoma. Cancer, 2009, 115, 4775-4782.	4.1	42
98	Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. Journal of Neuro-Oncology, 2009, 91, 271-277.	2.9	34
99	Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. Journal of Neuro-Oncology, 2009, 91, 359-367.	2.9	59
100	Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia. Journal of Neuro-Oncology, 2009, 93, 229-232.	2.9	26
101	Neurolymphomatosis: a rare metastatic complication of diffuse large B-Cell lymphoma. Journal of Neuro-Oncology, 2009, 95, 285-288.	2.9	30
102	Neoplastic Meningitisâ€‘Related Prognostic Significance of the Karnofsky Performance Status. Archives of Neurology, 2009, 66, 74-8.	4.5	53
103	Leptomeningeal metastasis. Current Opinion in Neurology, 2009, 22, 665-674.	3.6	47
104	Risk of neoplastic meningitis following surgical resection of cerebellar metastases. Journal of Neuro-Oncology, 2008, 89, 105-107.	2.9	8
105	CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. Journal of Neuro-Oncology, 2008, 89, 231-238.	2.9	19
106	Neoplastic meningitis. Current Neurology and Neuroscience Reports, 2008, 8, 249-258.	4.2	34
107	Myelomatous meningitis. Cancer, 2008, 112, 1562-1567.	4.1	32
108	Salvage chemotherapy with CPTâ€‘11 for recurrent temozolomideâ€‘refractory anaplastic astrocytoma. Cancer, 2008, 112, 2038-2045.	4.1	23

#	ARTICLE	IF	CITATIONS
109	Temozolomide for recurrent low-grade spinal cord gliomas in adults. <i>Cancer</i> , 2008, 113, 1019-1024.	4.1	62
110	Interferon- α for recurrent World Health Organization grade 1 intracranial meningiomas. <i>Cancer</i> , 2008, 113, 2146-2151.	4.1	104
111	Neoplastic Meningitis. <i>Oncologist</i> , 2008, 13, 967-977.	3.7	167
112	A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. <i>Neuro-Oncology</i> , 2008, 10, 208-215.	1.2	109
113	Anaplastic astrocytomas: biology and treatment. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 575-586.	2.8	8
114	SEQUENTIAL SALVAGE CHEMOTHERAPY FOR RECURRENT INTRACRANIAL HEMANGIOPERICYTOMA. <i>Neurosurgery</i> , 2008, 63, 720-727.	1.1	66
115	Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. <i>Blood</i> , 2007, 110, 1698-1698.	1.4	17
116	A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2007, 82, 207-209.	2.9	37
117	Chemotherapy for Brain Metastases due to Lung Cancer and Melanoma. <i>Cancer Treatment and Research</i> , 2007, 136, 199-213.	0.5	1
118	Salvage chemotherapy With CPT-11 for recurrent meningioma. <i>Journal of Neuro-Oncology</i> , 2006, 78, 271-276.	2.9	97
119	Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. <i>Cancer</i> , 2006, 106, 2021-2027.	4.1	74
120	Treatment options for glioblastoma. <i>Neurosurgical Focus</i> , 2006, 20, E19.	2.3	37
121	Cerebrospinal fluid-disseminated meningioma. <i>Cancer</i> , 2005, 103, 1427-1430.	4.1	62
122	Leukemia and the nervous system. <i>Current Oncology Reports</i> , 2005, 7, 66-73.	4.0	10
123	Neoplastic meningitis-related encephalopathy. <i>Journal of Neuro-Oncology</i> , 2005, 72, 185-189.	2.9	2
124	Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. <i>Journal of Neuro-Oncology</i> , 2005, 75, 71-83.	2.9	83
125	Central Nervous System Cancers Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2005, 3, 644.	4.9	66
126	Neoplastic Meningitis. <i>Seminars in Neurology</i> , 2004, 24, 363-374.	1.4	18

#	ARTICLE	IF	CITATIONS
127	Temozolomide for treatment-resistant recurrent meningioma. <i>Neurology</i> , 2004, 62, 1210-1212.	1.1	167
128	Neoplastic meningitis-related encephalopathy. <i>Neurology</i> , 2004, 63, 2159-2161.	1.1	37
129	Intracerebral meningiomas. <i>Current Treatment Options in Neurology</i> , 2004, 6, 297-305.	1.8	31
130	Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. <i>Cancer</i> , 2004, 100, 1213-1220.	4.1	56
131	Intracranial meningiomas: diagnosis and treatment. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 641-648.	2.8	59
132	Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. <i>Cancer</i> , 2003, 97, 3053-3060.	4.1	70
133	Combined-modality Treatment of Leptomeningeal Gliomatosis. <i>Neurosurgery</i> , 2003, 52, 324-330.	1.1	61
134	Lymphomatous Meningitis. <i>American Journal of Cancer</i> , 2002, 1, 423-434.	0.4	1
135	A Phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. <i>Cancer</i> , 2002, 94, 2675-2680.	4.1	91
136	Treatment of intracranial metastatic esthesioneuroblastoma. <i>Cancer</i> , 2002, 95, 243-248.	4.1	47
137	Salvage chemotherapy for recurrent spinal cord ependymoma. <i>Cancer</i> , 2002, 95, 997-1002.	4.1	82
138	Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2002, 56, 183-188.	2.9	73
139	Recurrent intracranial ependymoma in children: salvage therapy with oral etoposide. <i>Pediatric Neurology</i> , 2001, 24, 117-121.	2.1	57
140	A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. <i>Neuro-Oncology</i> , 2001, 3, 42-45.	1.2	69
141	Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis. <i>Journal of Clinical Oncology</i> , 1999, 17, 3110-3116.	1.6	393
142	Leptomeningeal metastases: a review of evaluation and treatment. , 1998, 37, 271-284.		113
143	Radioisotope CSF flow studies in leptomeningeal metastases. , 1998, 38, 135-140.		117
144	Carcinoma Meningitis Secondary to Non-“Small Cell Lung Cancer. <i>Archives of Neurology</i> , 1998, 55, 506.	4.5	130

#	ARTICLE	IF	CITATIONS
145	Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. <i>Journal of Neurosurgery</i> , 1997, 87, 694-699.	1.6	148
146	Chronic oral VP-16 for recurrent medulloblastoma. <i>Pediatric Neurology</i> , 1997, 17, 230-234.	2.1	54
147	Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy. , 1997, 35, 55-64.		95
148	Prognostic significance of sup 111 Indium-DTPA CSF flow studies in leptomeningeal metastases. <i>Neurology</i> , 1996, 46, 1674-1677.	1.1	151
149	Comparative spine imaging in leptomeningeal metastases. <i>Journal of Neuro-Oncology</i> , 1995, 23, 233-238.	2.9	108
150	Leptomeningeal metastasis. <i>Neurology</i> , 1990, 40, 435-435.	1.1	244
151	Phase I/II study of intraventricular and intrathecal ACNU for leptomeningeal neoplasia. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 23, 301-307.	2.3	29